Results 201 to 210 of about 9,771,651 (424)

Detection rate for ESR1 mutations is higher in circulating‐tumor‐cell‐derived genomic DNA than in paired plasma cell‐free DNA samples as revealed by ddPCR

Molecular Oncology, EarlyView.
Analysis of ESR1 mutations in plasma cell‐free DNA (cfDNA) is highly important for the selection of treatment in patients with breast cancer. Using multiplex‐ddPCR and identical blood draws, we investigated whether circulating tumor cells (CTCs) and cfDNA provide similar or complementary information for ESR1 mutations.
Stavroula Smilkou, Aliki Ntzifa, Victoria Tserpeli, Ioanna Balgkouranidou, Alkistis Papatheodoridi, Evangelia Razis, Helena Linardou, Christos Papadimitriou, Amanda Psyrri, Flora Zagouri, Stylianos Kakolyris, Evi Lianidou   +11 more
wiley   +1 more source

Medical Genetics in Clinical Practice [PDF]

, 2018
Two hundred and fifty-four patients were seen in the Genetic Clinics during 1973, the first full year of activity of the Department of Human Genetics, University of Cape Town. The current role of medical genetics in clinical practice is exemplified by an
Beighton, PH, Nelson, MM
core   +1 more source

Robust acute myeloid leukemia engraftment in humanized scaffolds using injectable biomaterials and intravenous xenotransplantation

Molecular Oncology, EarlyView.
Patient‐derived xenografts (PDXs) can be improved by implantation of a humanized niche. We tested different biomaterials and approaches, and demonstrate that the combination of an injectable biomaterial for scaffold creation plus an intravenous route for acute myeloid leukemia (AML) xenotransplantation provide the most convenient and robust approach to
Daniel Busa, Zdenka Herudkova, Jan Hyl, Jakub Vlazny, Filip Sokol, Kvetoslava Matulova, Adam Folta, Jakub Hynst, Lucy Vojtova, Leos Kren, Martin Repko, Zdenek Racil, Jiri Mayer, Martin Culen   +13 more
wiley   +1 more source

Abstracts of the joint meeting of the Clinical Genetics Society and the Clinical Molecular Genetics Society held on 19 and 20 April 1990 at University of Newcastle upon Tyne Medical School [PDF]

, 1990
Mary Porteous, John Burn, S Proctort, C. Geoffrey Woods, Sarah Bundey, A. Malcolm R. Taylor   +5 more
openalex   +1 more source

ABC of Clinical Genetics. Clinical genetic services. [PDF]

BMJ, 1989
openaire   +3 more sources

Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer

Molecular Oncology, EarlyView.
This study employed targeted metabolomic profiling to identify 302 distinct metabolites present in platelet‐rich plasma (PRP), revealing aberrant metabolic profiles amongst individuals diagnosed with colorectal cancer (CRC). Compared to carcinoembryonic antigen (CEA) and cancer antigen 19‐9 (CA199), our metabolite panel showed improved sensitivity ...
Zuojian Hu, Fenglin Shen, Yang Liu, Ziqing Zhong, Yongling Chen, Zhiyuan Xia, Cuiju Mo, Hongxiu Yu   +7 more
wiley   +1 more source

Molecular genetics of Alport syndrome: the clinical consequences [PDF]

, 1993
Bertrand Knebelmann, Corinne Antignac, Marie‐Claire Gubler, Jean‐Pierre Grünfeld   +3 more
openalex   +1 more source

Genetics, Clinical Features, and Long-Term Outcome of Noncompaction Cardiomyopathy.

Journal of the American College of Cardiology, 2018
J. I. van Waning, K. Caliskan, Y. Hoedemaekers, K. V. van Spaendonck‐Zwarts, A. Baas, S. M. Boekholdt, J. V. van Melle, A. Teske, F. Asselbergs, A. Backx, Gideon J. du Marchie Sarvaas, M. Dalinghaus, J. Breur, M. Linschoten, Laura A. Verlooij, I. Kardys, D. Dooijes, R. L. Lekanne Deprez, A. IJpma, Maarten P. van den Berg, Robert M.W. Hofstra, M. V. van Slegtenhorst, J. Jongbloed, D. Majoor-Krakauer   +23 more
semanticscholar   +1 more source

KMT2A degradation is observed in decitabine‐responsive acute lymphoblastic leukemia cells

Molecular Oncology, EarlyView.
We demonstrate that decitabine (DEC) not only degrades the DNA methyltransferase DNMT1 but also the leukemic driver lysine methyltransferase KMT2A likely due to structural similarity of the DNA‐binding CXXC domains. DEC influences KMT2A downstream processes and synergizes with menin inhibitor revumenib (REV) to decrease leukemic cell proliferation, and
Luisa Brock, Lina Benzien, Sandra Lange, Maja Huehns, Alexandra Runge, Catrin Roolf, Anett Sekora, Gudrun Knuebel, Hugo Murua Escobar, Christian Junghanss, Anna Richter   +10 more
wiley   +1 more source

Unveiling differential gene co-expression networks and its effects on levodopa-induced dyskinesia

iScience
Summary: Levodopa-induced dyskinesia (LID) refers to involuntary motor movements of chronic use of levodopa in Parkinson’s disease (PD) that negatively impact the overall well-being of people with this disease.
Tatiane Piedade de Souza, Gilderlanio Santana de Araújo, Leandro Magalhães, Giovanna C. Cavalcante, Arthur Ribeiro-dos-Santos, Camille Sena-dos-Santos, Caio Santos Silva, Gracivane Lopes Eufraseo, Alana de Freitas Escudeiro, Giordano Bruno Soares-Souza, Bruno Lopes Santos-Lobato, Ândrea Ribeiro-dos-Santos   +11 more
doaj